ARTICLE SUMMARY:
The current screening paradigm for heart disease is missing people at early stages, when diseases are most treatable. HeartSciences has taken a ubiquitous screening tool, the 12-lead ECG, and has, through the application of signal processing and artificial intelligence, turned it into a powerful tool that can detect diastolic dysfunction, an early indicator of most cardiac diseases.
While many serious diseases quietly lurk in an asymptomatic phase during which they could be treated to prevent undesirable outcomes, it is rarely cost-effective to screen the general population for their presence, especially when screening involves expensive imaging modalities and interpretation by specialists.
